New York, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment ...
Dublin, May 17, 2023 (GLOBE NEWSWIRE) -- The "Benign Prostate Hyperplasia (BPH) Treatment Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028 Segmented By ...
The Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market has seen significant attention due to the increasing prevalence of prostate-related conditions, particularly among the aging male ...
The global Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market is expected to reach a valuation of US$ 39.5 Bn in 2028, with demand growing at an average CAGR of 4.7% from 2022 to 2028. In ...
Treatment with vibegron reduced the average number of micturition episodes per day and the average number of daily urgency episodes compared with placebo. The Food and Drug Administration (FDA) has ...
Teleflex Incorporated announced the presentation of multiple clinical studies at the 2025 American Urological Association Annual Meeting in Las Vegas, highlighting advancements in treatments for ...
Treatment with botulinum toxin has proved no more effective than placebo at reducing symptoms in men with lower urinary tract symptoms (LUTS) due to benign prostate hyperplasia (BPH), show study ...
Benign prostatic hyperplasia (BPH) is extremely common in the aging man and may cause significant lower urinary tract symptoms (LUTS) necessitating treatment. Drug treatment is the mainstay of ...
Clinical studies have demonstrated that doxazosin therapy reduced blood pressure (BP) in patients with benign prostatic hyperplasia (BPH) who were hypertensive at baseline but not in patients who were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results